Susan Mesco

Head, Investor Relations at Insmed, Inc.

Susan Mesco

Susan Mesco

Head, Investor Relations at Insmed, Inc.

Overview
RelSci Relationships

158

Contact Data
Trying to get in touch with Susan Mesco? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Susan Mesco likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman & Chief Executive Officer at Insmed, Inc.

Relationship likelihood: Strong

Chief Technology Officer at Insmed, Inc.

Relationship likelihood: Strong

Chief People Strategy Officer at Insmed, Inc.

Relationship likelihood: Average

Chief Legal Officer at Insmed, Inc.

Relationship likelihood: Average

Executive Vice President & Chief Medical Officer at Insmed, Inc.

Relationship likelihood: Average

Chief Accounting Officer at Insmed, Inc.

Relationship likelihood: Average

Senior Director, Analytics at Insmed, Inc.

Relationship likelihood: Average

Senior Director, Regulatory Affairs at Insmed, Inc.

Relationship likelihood: Average

Chief Commercial Officer at Insmed, Inc.

Relationship likelihood: Average

Chief Financial Officer at Epizyme, Inc.

Relationship likelihood: Average

Paths to Susan Mesco
Potential Connections via
Relationship Science
You
Susan Mesco
Head, Investor Relations at Insmed, Inc.
Career History
Investor Relations Contact
Current

Pacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Head, Investor Relations
Current

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Other Affiliations

Susan Mesco is affiliated with Pacira Biosciences, Inc., Insmed, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Susan Mesco. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Susan Mesco's profile does not indicate a business or promotional relationship of any kind between RelSci and Susan Mesco.